Flutemetamol (18F): Difference between revisions
Jump to navigation
Jump to search
Rabin Bista (talk | contribs) Created page with "{{DISPLAYTITLE:Flutemetamol (<sup>18</sup>F)}} {{Infobox drug | drug_name = Flutemetamol (<sup>18</sup>F) | IUPAC_name = 2-[3-(<sup>18</sup>F)Fluoro-4-(methylam..." |
m Protected "Flutemetamol (18F)": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
(2 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
[[File:Flutemetamol Info.png|right|300px]] | |||
| | |||
| | |||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} |
Latest revision as of 21:09, 18 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Flutemetamol (18F) (trade name Vizamyl, by GE Healthcare) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18, used as a diagnostic tool for Alzheimer's disease.[1]
Mechanism of action
After the substance is given intravenously, it accumulates in beta amyloid plaques in the patient's brain, which thus become visible via positron emission tomography (PET).[1]